The aim of this analysis was to evaluate the efficacy of alpha- 
Introduction interrupted until resolution of toxicity, and resumed at 50% of the dose. Toxicity grading was according to the National Chronic myeloid leukemia (CML), a clonal disorder arising in Cancer Institute guidelines. 8 The dose was also reduced by early hematopoietic progenitor stem cells, begins with an 25% if the white blood cell count (WBC) was lower than indolent or chronic phase (CP) which is generally well-con-2 × 10 9 /l or if the platelet count was lower than 60 × 10 9 /l. trolled with conventional therapy. It eventually progresses to
The number of days of Ara-C was adjusted by ±2 days based the accelerated phase or blastic phase. 1, 2 In early CP-CML on the WBC and platelet count in the previous course. (diagnosis for less than 12 months), alpha-interferon (␣-IFN) produces complete hematological response (CHR) in 70-80% of patients, and complete cytogenetic response in 5-32%, Response criteria, prognostic models, and statistical depending on patient selection and treatment schedules. methods These cytogenetic responses are long-standing and confer a survival benefit, with 80% or more of patients remaining alive
Response criteria were as previously described. 3, 9 Complete and in remission at 8 years. 3 While prognostic factors, risk hematological remission (CHR) required a complete normalizgroups, outcome with ␣-IFN therapies, and survival are wellation of the peripheral counts (WBC р10 × 10 9 /l, platelet defined in early CP-CML, [4] [5] [6] little is known about the efficacy р450 × 10 9 /l), no immature cells in the peripheral blood and of ␣-IFN in late CP-CML, defined by a period of time from absence of all signs and symptoms of disease including diagnosis to therapy greater than 12 months. The early experipalpable splenomegaly. Patients achieving a CHR were ence with ␣-IFN therapy showed a decrease in responsiveness further categorized according to suppression of the Ph with increasing time from diagnosis. 7 Here we report on the chromosome as follows: no cytogenetic response, 100% Phlong-term follow-up results of patients in late CP-CML treated positive metaphases; minor cytogenetic response, 35-95% with different ␣-IFN-based regimens at our institution.
Ph-positive metaphases; partial cytogenetic response, Prognostic models from diagnosis to treatment, no significant differences were found ( Table 2 ). The median follow-up was 49 months (range, The 'overall' prognostic model 4 is based on values of hazard 1-149 months); 87 of the 137 patients have died. The median ratios, derived from solving a mathematical equation. The overall survival was 49 months, with an estimated 5-year sur-'overall' model identified five independent poor prognostic vival rate of 41% (Figure 1 ). CHR and cytogenetic response factors, by multivariate analysis: (1) age of 60 years or greater; rates were higher in the 67 patients treated with ␣-IFN plus (2) black race; (3) marrow basophils of 3% or greater; Ara-C than in the 70 patients who received ␣-IFN alone or (4) blood basophils of 7% or greater; and (5) cytogenetic with IFN-␥ or with HU, although the pretreatment characterclonal evolution. The 'synthesis' prognostic model 6 is based istics of the two groups were similar ( The association of patient and disease characteristics with and (5) splenomegaly of 10 cm or greater below the costal achievement of cytogenetic response are summarized in margin. Table 4 . Only low peripheral blood blast and basophil percentages, and normal hemoglobin levels were associated with
Statistical methods a higher incidence of any cytogenetic response (P Ͻ 0.05). When patients were subgrouped according to risk using progDifferences among variables were evaluated using the 2 test. nostic models, trends for differences in the incidence of cytoSurvival curves were plotted by the methods of Kaplan and genetic response were observed among various risk groups, Meier, and were compared by the log-rank test. 10, 11 which did not reach statistical significance (Table 4) . Pretreatment characteristics associated with statistically better survival experience, included smaller spleen size, lower percentages Results of peripheral blood and bone marrow blasts and basophils, and higher albumin levels (Table 4) . Survival was not signifi-
Study group
cantly different among risk group defined by prognostic models derived from characteristics at presentation (Table 4) . SurThe characteristics of the patients entered on the different ␣-vival by cytogenetic response was evaluated using a landmark IFN-based programs are detailed in Table 1. analysis at 12 months into therapy. Survival dated from 12 months into therapy by cytogenetic response is shown in Figure 2 . The estimated 6-year survival rates were 75% with
Response and outcome major cytogenetic response, 36% with minor cytogenetic response and 22% with other response patterns (P = 0.019). Of the 137 patients treated, 123 were evaluable for response. Seventy patients (57%) obtained CHR, and 19 (15% of the The characteristics and follow-up studies of patients who obtained major cytogenetic response had had prior short-term treatment (Ͻ2 months) with busulfan. At this time, 14 patients are still alive; seven remain on the same treatment, and have continued to have cytogenetic response; five major, two minor.
Discussion
In the ␣-IFN era, the therapeutic goal in early CP-CML has changed from control of hematological manifestations of the disease to suppression of the neoplastic clone, as defined by a decrease in Ph-positive cells and reconstitution of polyclonal hematopoiesis. 12 Patients in late chronic phase CML who are not eligible for allogeneic stem cell transplantation may be offered several therapeutic options with different therapeutic modalities may also be an inexpensive, easy to deliver, and relatively non-toxic approach to control CML disease to a minimum tumor burden. While prognostic factors, risk groups, outcome with ␣-IFN therapies, and survival are well-defined in early CP-CML, [4] [5] [6] little is known about the efficacy of ␣-IFN in late CP-CML, defined by a period of time from diagnosis to therapy greater than 12 months. This definition of late CP-CML is based on the early experience with ␣-IFN therapy, showing a decrease in responsiveness with increasing time from diagnosis. In advanced CML phases significant cytogenetic responses are reported in less than 10% of patients, 1, 7 and these patients are more often primarily resistant to ␣-IFN. 13, 14 In this study, ␣-IFN-based regimens induced an overall CHR rate of 57%, and a cytogenetic response rate of 15%, which was major in 8% and complete in only 2%. This emphasizes the need to (1) start ␣-IFN treatment early in eligible patients, low-dose Ara-C was associated with significantly higher CHR rates compared with ␣-IFN alone, a trend for better cytogenetic response rates, and with significantly longer 3-year Pre, prior to therapy; HU, hydroxyurea; HHT, homoharringtonine, ␣-IFN, alpha interferon; Bus, busulfan; Ara-C, cytosine arabinoside, ␥-IFN, gamma interferon; CR, PR, MR, complete, partial and minor response; CG, cytogenetic; CHR, PHR, complete and partial hematological response; NA, NE, ND, not available, not evaluable, not done; IM, insufficient metaphases. estimated survival. 15 These promising results have been molecules, preventing proliferation of Ph-positive hematopoietic progenitor. [21] [22] [23] It is possible that CML progression is recently confirmed. 16 Our results show that ␣-IFN in combination with Ara-C yields higher cytogenetic response rates associated with increased proliferation, further decreased cytoadhesion and poor maturation, and development of compared with ␣-IFN alone or in combination with IFN-␥ or HU. Despite an early trend for better survival with ␣-IFN plus mechanisms of resistance bypassing the ␣-IFN effects. The results of this study emphasize the need to define better bioAra-C, the overall survival difference was not significant.
Our results confirm the association between achievement logically and prognostically late CP-CML patients, which may help in developing new therapeutic strategies for advanced of a cytogenetic response with ␣-IFN-based regimens and survival prolongation in patients with late CP-CML, as was well CML phases. Interleukin-1 has been implicated in CML disease progression, and CML progenitors from patients with established in early CP. 3, [17] [18] [19] The estimated 6-year survival rates were 75% for 10 patients with major cytogenetic advanced disease produce large amounts of interleukin-1␤. 24, 25 Inhibition of apoptosis by p210 BCR-ABL expression response, 36% for nine patients with minor cytogenetic response, and 22% for patients with no cytogenetic response might contribute to clonal expansion in CML, 26 and agents such as retinoids, may enhance apoptosis in CML and (Figure 2) . Some pretreatment characteristics, including spleen size, peripheral blood and bone marrow blasts and basophils, improve patient outcome, when combined with anti-CML agents. 27, 28 All-trans retinoic acid (ATRA) inhibited progenitors and albumin were associated with statistically significant better survival experience, similarly to early CP-CML patients.
in CML, especially in more advanced CML phases, 27 and the combination of ATRA and ␣-IFN inhibited GM colony growth When patients were subgrouped according to the prognostic models, no significant differences in response to therapy and in CML, and stimulated GM colony growth in healthy controls. 28 These in vitro findings suggest that ATRA plus ␣-IFN in survival outcome were observed among various risk groups. This is probably because the prognostic models defined risk could play a role in the treatment of CML patients, although clinical trials of ATRA as a single agent have shown very modgroups based on presentation characteristics, rather than the features exhibited in late CP-CML, prior to the start of therapy.
est activity in ␣-IFN resistant and advanced phase CML patients.
29,30
A relationship may exist between CML progression, and reduced efficacy of ␣-IFN mechanisms of action in CML. In
In summary, this study confirms the modest activity of ␣-IFN-based regimens in late CP-CML patients, and supports the vitro studies have shown that ␣-IFN preferentially suppressed the growth of Ph-positive CFU-GM. 20 Cells from CML patients need to define better the predictors for response and survival, and to develop investigational strategies aimed at improving have decreased expression of cell surface adhesion molecules, and incubation with ␣-IFN increased the expression of these cytogenetic response in late CP-CML. 
